Mostrar el registro sencillo del ítem
dc.contributor.author
Patrucco, Liliana
dc.contributor.author
Cristiano, Edgardo
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Sánchez, Francisco
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Miguez, Jimena
dc.contributor.author
Rojas, Juan Ignacio
dc.date.available
2021-01-18T16:29:09Z
dc.date.issued
2019-07
dc.identifier.citation
Patrucco, Liliana; Cristiano, Edgardo; Sánchez, Francisco; Miguez, Jimena; Rojas, Juan Ignacio; Real-World Effectiveness and Safety of Fingolimod in Patients With Relapsing Remitting Multiple Sclerosis; Lippincott Williams; Clinical Neuropharmacology; 42; 5; 7-2019; 163-166
dc.identifier.issn
0362-5664
dc.identifier.uri
http://hdl.handle.net/11336/122870
dc.description.abstract
Objectives The aim of this prospective observational postmarketing study was to evaluate fingolimod effectiveness in a real-world setting in Buenos Aires, Argentina. Methods Relapsing remitting multiple sclerosis patients who had been prescribed fingolimod owing to treatment failure and had at least greater than or equal to 24 months of follow-up were included during August 2013 and June 2018. Three-monthly clinical evaluations and 12-monthly magnetic resonance were performed. Demographic and clinical variables were described as well as the safety and the effectiveness outcomes that included the proportion of patients free from clinical relapses, from disability progression, from new or enlarging T2 or T1 gadolinium-enhancing lesions on annual magnetic resonance imaging, and from any disease activity during the follow-up. Results A total of 97 patients were included (68% female [n = 66]; mean ± SD age, 30 ± 10.5 years; mean ± SD disease duration, 6.5 ± 3.1 years; mean ± SD Expanded Disability Status Scale, 3.5 ± 1; mean ± SD fingolimod use, 30 ± 13 months [range, 18-56 months]). One hundred percent (97) used previous disease-modifying therapy, mainly interferons (87%; n = 84). Fourteen patients (14.4%) discontinued/withdrew fingolimod (10 owing to disease activity and 4 owing to tolerance and personal decisions). Eighty-two percent were free from clinical relapses, and 85% were free from disability progression; 75% of patients remained free from new or newly enlarging T2 lesions, and 78% of patients were free from gadolinium enhancing lesions. The proportion of patients free from any disease activity was 54%. Conclusions The effectiveness of fingolimod in a newly real-world setting was consistent with information provided from phase III clinical trials.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Lippincott Williams
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
ARGENTINA
dc.subject
FINGOLIMOD
dc.subject
MULTIPLE SCLEROSIS
dc.subject.classification
Neurociencias
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Básica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Real-World Effectiveness and Safety of Fingolimod in Patients With Relapsing Remitting Multiple Sclerosis
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2020-11-19T21:37:48Z
dc.journal.volume
42
dc.journal.number
5
dc.journal.pagination
163-166
dc.journal.pais
Estados Unidos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Philadelphia
dc.description.fil
Fil: Patrucco, Liliana. Hospital Italiano; Argentina
dc.description.fil
Fil: Cristiano, Edgardo. Hospital Italiano; Argentina
dc.description.fil
Fil: Sánchez, Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
dc.description.fil
Fil: Miguez, Jimena. Hospital Italiano; Argentina
dc.description.fil
Fil: Rojas, Juan Ignacio. Hospital Italiano; Argentina
dc.journal.title
Clinical Neuropharmacology
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://Insights.ovid.com/crossref?an=00002826-900000000-99528
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1097/WNF.0000000000000358
Archivos asociados